NEW YORK – ABL Europe and France's Odimma Therapeutics said on Tuesday they have inked a collaboration to advance Odimma's personalized cancer immunization platform, ODI-2001.
For its part of the collaboration, Paris-based ABL, an Institut Mérieux subsidiary contract development and manufacturing organization focused on good manufacturing practice-grade viral vectors, will provide the viral component for ODI-2001. The viral vector plays a crucial role in the mechanism of ODI-2001, since it carries the DNA vector expressing personalized neoantigens.
By delivering these personalized neoantigens, Odimma's therapy is designed to allow patients' own immune cells to recognize and attack tumor cells. The treatment is meant to be produced quickly, and the firm has set no limits on the number of neoantigens ODI-2001 can target.
Odimma noted in a statement that the platform has demonstrated a powerful immune response and anti-tumor effects in mouse models and is ready to enter the clinic.